Atara Biotherape Stock Price, News & Analysis

Atara Biotherapeutics (Nasdaq: ATRA) has not yet initiated the Biologics License Application (BLA) for tab-cel^® (tabelecleucel), under Phase 3 development for EBV-positive post-transplant lymphoproliferative disease. The Company awaits a procedural decision from the FDA regarding historical data presentation in the BLA. Despite the delay, Atara remains on track to complete the BLA filing in Q3 2021, with an objective response rate of 50% reported in the pivotal study. Ongoing discussions with the FDA are described as constructive.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced a public offering of 5,102,041 shares at $24.50 each and pre-funded warrants for 2,040,816 shares at $24.4999, totaling approximately $175 million in gross proceeds. The offering is set to close on December 11, 2020, pending customary conditions. Citigroup, Evercore ISI, and Mizuho Securities serve as joint book-running managers, with an option for underwriters to purchase an additional 1,071,428 shares. The offering is conducted under a previously filed registration statement with the SEC.

Atara Biotherapeutics (Nasdaq: ATRA) has initiated a public offering of $150 million in common stock, with a potential additional $22.5 million from underwriters. The offering is subject to market conditions, and there are no guarantees regarding its completion or terms. The shares will be sold by Atara Biotherapeutics, leveraging a previously filed shelf registration statement with the SEC. Citigroup, Evercore ISI, and Mizuho Securities are acting as joint book-running managers for this offering.

Atara Biotherapeutics (Nasdaq: ATRA) announced the first preclinical evaluation of ATA3219, a novel off-the-shelf CAR T-cell therapy targeting CD19, and data from its Phase II study of tab-cel® for EBV-driven diseases. The results showcased ATA3219's potent antitumor activity and safety in preclinical models. Atara plans to submit an IND for ATA3219 in 2021 following a successful FDA meeting. Additionally, tab-cel® demonstrated high response rates in patients with life-threatening EBV viremia, with an overall survival rate of 100% at one year.

Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) have entered a global license agreement for mesothelin-directed CAR T-cell therapies targeting solid tumors. This collaboration involves the development candidate ATA3271 and an autologous version, ATA2271. Atara will oversee IND-enabling studies while Bayer manages the IND submission and clinical development. Atara receives an upfront payment of $60 million and can earn up to $610 million in milestones plus royalties on net sales. This partnership aims to enhance the development of off-the-shelf CAR T-cell therapies for challenging cancer types.

Atara Biotherapeutics, a leader in T-cell immunotherapy, has announced participation in two upcoming virtual conferences. The Stifel 2020 Virtual Healthcare Conference is set for November 18, 2020, featuring a fireside chat with CEO Pascal Touchon. The Evercore ISI 3rd Annual Virtual HealthCONx Conference will take place on December 2, 2020, with chats including Pascal Touchon and Jakob Dupont, Global Head of Research and Development. Both events will be accessible via live webcasts on the company's website, with archived replays available for 14 days.

Atara Biotherapeutics (Nasdaq: ATRA) announced promising 15-month safety and efficacy data for ATA188, a treatment for progressive multiple sclerosis (MS), presented at the European Charcot Foundation's 28th Annual Meeting. In a Phase 1a study, 50% of patients showed sustained disability improvement, indicating a potential treatment effect. Atara plans to enhance its investment in the ATA188 program, expanding the randomized controlled trial to at least 64 patients and focusing on disability improvement as the primary endpoint. This treatment addresses a significant unmet need in MS.

Atara Biotherapeutics (Nasdaq: ATRA) announced the preclinical evaluation of ATA3271, an allogeneic EBV CAR T-cell therapy targeting mesothelin for solid tumors. The data, presented at the SITC 2020, demonstrate potent antitumor activity of ATA3271 in both in vitro and in vivo settings, with no evident toxicities. The therapy retained function despite high PD-L1 expression in tumor environments. Additionally, the FDA accepted an IND application for another therapy, ATA2271. These advancements signal a step forward in Atara's commitment to transformative cancer therapies.

Atara Biotherapeutics (Nasdaq: ATRA) reported its Q3 2020 financial results, revealing a net loss of $74.3 million, or $0.92 per share. Despite a cash balance of $327.2 million sufficient to fund operations into 2022, R&D expenses increased to $59.9 million due to expanding clinical activities. Notably, the interim analysis of tab-cel® for relapsed-refractory EBV+ PTLD showed a 50% objective response rate. Atara plans to submit a BLA for tab-cel® by year-end 2020 and an EU MAA in H2 2021, further advancing their allogeneic T-cell therapies.